These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26999469)

  • 1. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?
    El-Jawahri A; Kim HT; Steensma DP; Cronin AM; Stone RM; Watts CD; Chen YB; Cutler CS; Soiffer RJ; Abel GA
    Bone Marrow Transplant; 2016 Aug; 51(8):1121-6. PubMed ID: 26999469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
    Abel GA; Koreth J
    Curr Opin Hematol; 2013 Mar; 20(2):150-6. PubMed ID: 23298879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
    Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
    J Clin Oncol; 2013 Jul; 31(21):2662-70. PubMed ID: 23797000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
    Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ
    Br J Haematol; 2006 Oct; 135(2):201-9. PubMed ID: 16939494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
    Abel GA; Kim HT; Hantel A; Steensma DP; Stone R; Habib A; Ho VT; Wadleigh M; El-Jawahri A; Alyea EP; DeAngelo DJ; Koreth J; Antin JH; Soiffer RJ; Cutler C
    Leukemia; 2021 Apr; 35(4):1166-1175. PubMed ID: 33204012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
    Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic cell transplantation for myelodysplastic syndrome.
    Deeg HJ
    Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
    Finke J; Nagler A
    Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.
    Deschler B; Ihorst G; Schnitzler S; Bertz H; Finke J
    Bone Marrow Transplant; 2018 May; 53(5):565-575. PubMed ID: 29330399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities.
    Lee SE; Kim YJ; Yahng SA; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Eur J Haematol; 2011 Dec; 87(6):510-20. PubMed ID: 21883477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
    Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?
    Marcondes M; Deeg HJ
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):67-77. PubMed ID: 18342814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.